Connect Biopharma Holdings (CNTB)
NASDAQ:CNTB
CNTB Stock Chart & Stats
$2.82
$0.04(3.94%)
At close: 4:00 PM EST
$2.82
$0.04(3.94%)
Day’s Range― - ―
52-Week Range$0.61 - $3.82
Previous CloseN/A
Volume1.98K
Average Volume (3M)97.97K
Market Cap
$159.39M
Enterprise Value$121.74M
Total Cash (Recent Filing)$44.34M
Total Debt (Recent Filing)$690.00K
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding56,521,282
10 Day Avg. Volume111,495
30 Day Avg. Volume97,966
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.74
Price to Sales (P/S)2452.52
P/FCF Ratio-3.04
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue1.90K
Enterprise Value/Gross Profit1.90K
Enterprise Value/Ebitda-4.26
Forecast
1Y Price Target
$8.38Price Target Upside197.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.26
Revenue Forecast (FY)$51.69M
Bulls Say, Bears Say
Bulls Say
Acute Hospital Use And Dosing StrategyIntravenous dosing may enable fast symptom relief in emergency and hospital settings with a straightforward transition to subcutaneous dosing for chronic care, expanding potential clinical use cases.
Clinical DifferentiationPhase 1 intravenous data demonstrated rapid and substantial lung function improvements compared with the subcutaneous formulation and existing biologics, supporting a differentiated efficacy profile for acute exacerbations.
Partnered China Program And Indication ExpansionA partner‑conducted Phase 3 trial in China showed durable symptom control and good tolerability in atopic dermatitis, creating a pathway to pursue skin disease markets outside China while retaining economic interest in the China program.
Bears Say
Clinical And Regulatory Execution RiskKey Phase 2 and Phase 3 readouts and subsequent regulator discussions remain pending, creating execution risk that could affect approval prospects and market access.
Financing RiskThe program may require additional financing to support late‑stage trials and commercialization, which could lead to shareholder dilution or increased market pressure if capital conditions tighten.
Market Sentiment And Competitive/geopolitical RisksA sharp share sell‑off after trial updates may reflect investor uncertainty, and competition, regulatory hurdles or geopolitical factors could prolong valuation weakness or increase downside risk.
Connect Biopharma Holdings News
CNTB FAQ
What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $0.60 and its highest was $3.82 in the past 12 months.
What is Connect Biopharma Holdings’s market cap?
Connect Biopharma Holdings’s market cap is $159.39M.
When is Connect Biopharma Holdings’s upcoming earnings report date?
Connect Biopharma Holdings’s upcoming earnings report date is May 14, 2026 which is in 31 days.
How were Connect Biopharma Holdings’s earnings last quarter?
Connect Biopharma Holdings released its earnings results on Mar 31, 2026. The company reported -$0.271 earnings per share for the quarter, missing the consensus estimate of -$0.261 by -$0.01.
Is Connect Biopharma Holdings overvalued?
According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
Does Connect Biopharma Holdings pay dividends?
Connect Biopharma Holdings does not currently pay dividends.
What is Connect Biopharma Holdings’s EPS estimate?
Connect Biopharma Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Connect Biopharma Holdings have?
Connect Biopharma Holdings has 56,521,282 shares outstanding.
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Connect Biopharma Holdings reported an EPS of -$0.271 in its last earnings report, missing expectations of -$0.261. Following the earnings report the stock price went up 3.817%.
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
Currently, no hedge funds are holding shares in CNTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Connect Biopharma Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.38 (197.16% Upside)
$8.38 (197.16% Upside)
Hedge Fund Trend
Increased
By 792.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.8%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.87%
Trailing 12-Months
Company Description
Connect Biopharma Holdings
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
CNTB Stock 12 Month Forecast
Average Price Target
$8.38
▲(197.16% Upside)
Technical Analysis
Scinai Immunotherapeutics
―
GT Biopharma
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Ownership Overview
23.29% Insiders
0.04% Mutual Funds
11.84% Other Institutional Investors
64.73% Public Companies and
Individual Investors